Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China

NCT01933646 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2015-01-07

No results posted yet for this study

Summary

Evaluate the burden of invasive group B streptococcal (GBS) disease in young infants (up to 90 days of age) in China, in terms of incidence, case fatality rate and serotype distribution

Conditions

  • Invasive Group B Streptococcal Disease

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Principal Investigators

  • Novartis Vaccines · Novartis Vaccines

Eligibility

Max Age
90 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01933646 on ClinicalTrials.gov